190 related articles for article (PubMed ID: 35013118)
1. Neurokinin-1 receptor promotes non-small cell lung cancer progression through transactivation of EGFR.
Zhang XW; Li L; Hu WQ; Hu MN; Tao Y; Hu H; Miao XK; Yang WL; Zhu Q; Mou LY
Cell Death Dis; 2022 Jan; 13(1):41. PubMed ID: 35013118
[TBL] [Abstract][Full Text] [Related]
2. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
3. PLCγ1‑dependent invasion and migration of cells expressing NSCLC‑associated EGFR mutants.
Mittal S; Kamath A; Joseph AM; Rajala MS
Int J Oncol; 2020 Oct; 57(4):989-1000. PubMed ID: 32945365
[TBL] [Abstract][Full Text] [Related]
4. R2-8018 reduces the proliferation and migration of non-small cell lung cancer cells by disturbing transactivation between M3R and EGFR.
Lan L; Wang H; Yang R; Liu F; Bi Q; Wang S; Wei X; Yan H; Su R
Life Sci; 2019 Oct; 234():116742. PubMed ID: 31401315
[TBL] [Abstract][Full Text] [Related]
5. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P.
Nizam E; Erin N
Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097
[TBL] [Abstract][Full Text] [Related]
6. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
7. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
8. TGFβ regulates NK1R-Tr to affect the proliferation and apoptosis of breast cancer cells.
Wang L; Wang N; Zhang R; Dong D; Liu R; Zhang L; Ji W; Yu M; Zhang F; Niu R; Zhou Y
Life Sci; 2020 Sep; 256():117674. PubMed ID: 32380077
[TBL] [Abstract][Full Text] [Related]
9. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
[TBL] [Abstract][Full Text] [Related]
10. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.
Whitsett TG; Cheng E; Inge L; Asrani K; Jameson NM; Hostetter G; Weiss GJ; Kingsley CB; Loftus JC; Bremner R; Tran NL; Winkles JA
Am J Pathol; 2012 Jul; 181(1):111-20. PubMed ID: 22634180
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.
Galvani E; Giovannetti E; Saccani F; Cavazzoni A; Leon LG; Dekker H; Alfieri R; Carmi C; Mor M; Ardizzoni A; Petronini PG; Peters GJ
Neoplasia; 2013 Jan; 15(1):61-72. PubMed ID: 23359111
[TBL] [Abstract][Full Text] [Related]
12. Roles of full-length and truncated neurokinin-1 receptors on tumor progression and distant metastasis in human breast cancer.
Zhou Y; Zhao L; Xiong T; Chen X; Zhang Y; Yu M; Yang J; Yao Z
Breast Cancer Res Treat; 2013 Jul; 140(1):49-61. PubMed ID: 23807418
[TBL] [Abstract][Full Text] [Related]
13. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
14. FoxO3a inhibiting expression of EPS8 to prevent progression of NSCLC: A new negative loop of EGFR signaling.
Wen Q; Jiao X; Kuang F; Hou B; Zhu Y; Guo W; Sun G; Ba Y; Yu D; Wang D; Zhang F; Qiao HC; Wang S; Tang S; Qiao H
EBioMedicine; 2019 Feb; 40():198-209. PubMed ID: 30738830
[TBL] [Abstract][Full Text] [Related]
15. ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition.
Buonato JM; Lazzara MJ
Cancer Res; 2014 Jan; 74(1):309-19. PubMed ID: 24108744
[TBL] [Abstract][Full Text] [Related]
16. RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer.
Kaneto N; Yokoyama S; Hayakawa Y; Kato S; Sakurai H; Saiki I
Cancer Sci; 2014 Jul; 105(7):788-94. PubMed ID: 24750242
[TBL] [Abstract][Full Text] [Related]
17. IRS4 promotes the progression of non-small cell lung cancer and confers resistance to EGFR-TKI through the activation of PI3K/Akt and Ras-MAPK pathways.
Hao P; Huang Y; Peng J; Yu J; Guo X; Bao F; Dian Z; An S; Xu TR
Exp Cell Res; 2021 Jun; 403(2):112615. PubMed ID: 33894221
[TBL] [Abstract][Full Text] [Related]
18. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer.
Garon EB; Pietras RJ; Finn RS; Kamranpour N; Pitts S; Márquez-Garbán DC; Desai AJ; Dering J; Hosmer W; von Euw EM; Dubinett SM; Slamon DJ
J Thorac Oncol; 2013 Mar; 8(3):270-8. PubMed ID: 23399957
[TBL] [Abstract][Full Text] [Related]
19. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
[TBL] [Abstract][Full Text] [Related]
20. Endogenous thrombopoietin promotes non-small-cell lung carcinoma cell proliferation and migration by regulating EGFR signalling.
Zou Z; Fan X; Liu Y; Sun Y; Zhang X; Sun G; Li X; Xu S
J Cell Mol Med; 2020 Jun; 24(12):6644-6657. PubMed ID: 32337844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]